VYDURAX Trademark

Trademark Overview


On Thursday, October 31, 2019, a trademark application was filed for VYDURAX with the United States Patent and Trademark Office. The USPTO has given the VYDURAX trademark a serial number of 88676055. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Tuesday, March 14, 2023. This trademark is owned by Biohaven Pharmaceutical Holding CompanyLtd.. The VYDURAX trademark is filed in the Pharmaceutical Products category with the following description:

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, alzheimer's disease (AD), amyotrophic lateral scler...
vydurax

General Information


Serial Number88676055
Word MarkVYDURAX
Filing DateThursday, October 31, 2019
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateTuesday, March 14, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 11, 2020

Trademark Statements


Goods and ServicesMedicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), huntington's disease, lewy body dementia, frontotemporal dementia, vascular dementia, parkinson's disease, cognitive impairment of aging, progressive multiple sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to nmda receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, post traumatic stress disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, obsessive compulsive disorder (OCD), hoarding, trichotillomania, eating disorders, generalized anxiety disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, attention deficit disorder (ADD), pervasive developmental disorders (PDD), asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use; all of the foregoing specifically excluding medicated and pharmaceutical preparations and substances for the treatment or management of respiratory diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateTuesday, March 14, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBIOHAVEN PHARMACEUTICAL IRELAND DAC
Party Type21 - New Owner After Publication
Legal Entity Type99 - Other
AddressRingaskiddy CountyCor
IE

Party NameBiohaven Pharmaceutical Holding CompanyLtd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Party NameBiohaven Pharmaceutical Holding CompanyLtd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressNew Haven, CT 06510

Trademark Events


Event DateEvent Description
Tuesday, March 14, 2023ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Tuesday, March 14, 2023ABANDONMENT - AFTER PUBLICATION
Monday, March 13, 2023TEAS EXPRESS ABANDONMENT RECEIVED
Thursday, October 27, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 27, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 27, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 27, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 27, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 3, 2022SOU EXTENSION 5 GRANTED
Thursday, September 22, 2022SOU EXTENSION 5 FILED
Monday, October 3, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 22, 2022TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, April 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 6, 2022SOU EXTENSION 4 GRANTED
Wednesday, April 6, 2022SOU EXTENSION 4 FILED
Wednesday, April 6, 2022TEAS EXTENSION RECEIVED
Thursday, October 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 5, 2021SOU EXTENSION 3 GRANTED
Tuesday, October 5, 2021SOU EXTENSION 3 FILED
Tuesday, October 5, 2021TEAS EXTENSION RECEIVED
Tuesday, April 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 2, 2021SOU EXTENSION 2 GRANTED
Friday, April 2, 2021SOU EXTENSION 2 FILED
Friday, April 2, 2021TEAS EXTENSION RECEIVED
Wednesday, October 7, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 5, 2020SOU EXTENSION 1 GRANTED
Monday, October 5, 2020SOU EXTENSION 1 FILED
Monday, October 5, 2020TEAS EXTENSION RECEIVED
Tuesday, April 7, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 11, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2020PUBLISHED FOR OPPOSITION
Wednesday, January 22, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 9, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 7, 2020ASSIGNED TO EXAMINER
Tuesday, November 5, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 4, 2019NEW APPLICATION ENTERED